Charles Schwab Investment Management Inc. Has $2.06 Million Stake in Arcturus Therapeutics Holdings Inc. $ARCT

Charles Schwab Investment Management Inc. decreased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 6.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 194,629 shares of the biotechnology company’s stock after selling 13,173 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.72% of Arcturus Therapeutics worth $2,061,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARCT. Byrne Asset Management LLC lifted its stake in shares of Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock worth $31,000 after buying an additional 1,365 shares during the last quarter. US Bancorp DE raised its holdings in Arcturus Therapeutics by 218.9% in the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,329 shares during the period. GAMMA Investing LLC raised its holdings in Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock worth $550,000 after acquiring an additional 5,085 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in Arcturus Therapeutics during the 4th quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP grew its holdings in Arcturus Therapeutics by 13.7% in the 4th quarter. Brevan Howard Capital Management LP now owns 12,305 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 1,486 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Down 1.7%

Shares of ARCT stock opened at $17.01 on Monday. The company has a market capitalization of $461.99 million, a P/E ratio of -7.63 and a beta of 2.38. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.04 and a 12-month high of $25.88. The firm has a 50-day moving average price of $14.58 and a 200 day moving average price of $13.36.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The firm had revenue of $28.30 million during the quarter, compared to analysts’ expectations of $17.64 million. As a group, research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, August 12th. Canaccord Genuity Group lowered their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Leerink Partners reduced their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a research report on Friday, August 22nd. Citigroup reissued a “buy” rating and issued a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Finally, Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $50.57.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.